Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Dr Peter Chapman

Peter Chapman

BSc, M.D(Otago) FRACP, PGDipMSM(Otago)

Email Peter.Chapman@cdhb.health.nz

Peter is a Rheumatologist and Clinical Director of Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board.

He has a broad range of interests in Rheumatology and is involved in undergraduate and postgraduate education.

^ Top of page

Publications

Becker, M., Graf, N., Sauter, R., Allanore, Y., Curram, J., . . ., EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis. Annals of the Rheumatic Diseases, 78(9), 1242-1248. doi: 10.1136/annrheumdis-2019-215145

Stamp, L. K., Chapman, P., Hudson, B., Frampton, C., Hamilton, G., & Judd, A. (2019). The challenges of managing gout in primary care: Results of a best-practice audit. Australian Journal of General Practice, 48(9), 631-637. doi: 10.31128/AJGP-04-19-4909

Sobanski, V., Giovannelli, J., Allanore, Y., Riemekasten, G., Airò, P., Vettori, S., … and the EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis. Arthritis & Rheumatology, 71(9), 1553-1570. doi: 10.1002/art.40906

Wu, W., Jordan, S., Graf, N., de Oliveira Pena, J., Curram, J., Allanore, Y., … EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 78(5), 648-656. doi: 10.1136/annrheumdis-2018-213455

Bursill, D., Taylor, W. J., Terkeltaub, R., Kuwabara, M., Merriman, T. R., Grainger, R., … Chapman, P. T., … Stamp, L. K., … Dalbeth, N. (2019). Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care & Research, 71(3), 427-434. doi: 10.1002/acr.23607

Journal - Research Article

Becker, M., Graf, N., Sauter, R., Allanore, Y., Curram, J., . . ., EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis. Annals of the Rheumatic Diseases, 78(9), 1242-1248. doi: 10.1136/annrheumdis-2019-215145

Bursill, D., Taylor, W. J., Terkeltaub, R., Kuwabara, M., Merriman, T. R., Grainger, R., … Chapman, P. T., … Stamp, L. K., … Dalbeth, N. (2019). Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care & Research, 71(3), 427-434. doi: 10.1002/acr.23607

Wu, W., Jordan, S., Graf, N., de Oliveira Pena, J., Curram, J., Allanore, Y., … EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 78(5), 648-656. doi: 10.1136/annrheumdis-2018-213455

Sobanski, V., Giovannelli, J., Allanore, Y., Riemekasten, G., Airò, P., Vettori, S., … and the EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis. Arthritis & Rheumatology, 71(9), 1553-1570. doi: 10.1002/art.40906

Stamp, L. K., Chapman, P., Hudson, B., Frampton, C., Hamilton, G., & Judd, A. (2019). The challenges of managing gout in primary care: Results of a best-practice audit. Australian Journal of General Practice, 48(9), 631-637. doi: 10.31128/AJGP-04-19-4909

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Merriman, T. R., Wright, D. F. B., … Dalbeth, N. (2019). Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response: In search of a minimum effective oxypurinol concentration. Clinical & Translational Science. Advance online publication. doi: 10.1111/cts.12686

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research & Therapy, 20, 255. doi: 10.1186/s13075-018-1755-0

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 57(12), 2183-2189. doi: 10.1093/rheumatology/key237

Yeo, E., Palmer, S. C., Chapman, P. T., Frampton, C., & Stamp, L. K. (2018). Serum urate levels and therapy in adults treated with long-term dialysis: A retrospective cross-sectional study. Internal Medicine Journal. Advance online publication. doi: 10.1111/imj.14163

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: A post hoc analysis of a randomized controlled trial. Arthritis Research & Therapy, 19(1), 283. doi: 10.1186/s13075-017-1491-x

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 76(9), 1522-1528. doi: 10.1136/annrheumdis-2016-210872

McQueen, F. M., Chapman, P., Pollock, T., D’Souza, D., Lee, A. C., Dalbeth, N., Stamp, L., … Doyle, A. (2017). Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. Arthritis Research & Therapy, 19, 241. doi: 10.1186/s13075-017-1433-7

Wright, S., Chapman, P. T., Frampton, C., O'Donnell, J. L., Raja, R., & Stamp, L. K. (2017). Management of gout in a hospital setting: A lost opportunity. Journal of Rheumatology, 44(10), 1493-1498. doi: 10.3899/jrheum.170387

Farquhar, H. J., McGettigan, B., Chapman, P. T., O'Donnell, J. L., Frampton, C., & Stamp, L. K. (2017). Incidence of anti-neutrophil cytoplasmic antibody-associated vasculitis before and after the February 2011 Christchurch Earthquake. Internal Medicine Journal, 47(1), 57-61. doi: 10.1111/imj.13246

Stamp, L. K., Haslett, J., Chapman, P., O'Donnell, J., Raja, R., Rothwell, A., Frampton, C., & Hooper, G. (2017). Rates of joint replacement surgery in New Zealand, 1999-2015: A comparison of rheumatoid arthritis and osteoarthritis. Journal of Rheumatology, 44(12), 1823-1827. doi: 10.3899/jrheum.170551

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases, 76(12), 2065-2070. doi: 10.1136/annrheumdis-2017-211873

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Stamp, L. K., Chapman, P. T., & Palmer, S. C. (2016). Allopurinol and kidney function: An update. Joint Bone Spine, 83, 19-24. doi: 10.1016/j.jbspin.2015.03.013

Johnston, M. E., Treharne, G. J., Chapman, P. T., & Stamp, L. K. (2015). Patient information about gout: An international review of existing educational resources. Journal of Rheumatology, 42(6), 975-978. doi: 10.3899/jrheum.141442

Stamp, L. K., Chapman, P. T., Francis, J., Beckert, L., Frampton, C., Watts, R. A., & O'Donnell, J. L. (2015). Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. Arthritis Research & Therapy, 17, 333. doi: 10.1186/s13075-015-0852-6

Stamp, L. K., & Chapman, P. T. (2014). Urate-lowering therapy: Current options and future prospects for elderly patients with gout. Drugs & Aging, 31(11), 777-786. doi: 10.1007/s40266-014-0214-0

Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J. M., Zhang, M., & Chapman, P. T. (2013). Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: A pilot randomized controlled trial. Arthritis & Rheumatism, 65(6), 1636-1642. doi: 10.1002/art.37925

Stamp, L. K., & Chapman, P. T. (2013). Gout and its comorbidities: Implications for therapy. Rheumatology, 52(1), 34-44. doi: 10.1093/rheumatology/kes211

Khan, E. A. R., Stamp, L. K., O'Donnell, J. L., & Chapman, P. T. (2013). Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999–2008. International Journal of Rheumatic Diseases, 16(1), 19-23. doi: 10.1111/1756-185x.12008

Prowse, R. L., Dalbeth, N., Kavanaugh, A., Adebajo, A. O., Gaffo, A. L., Terkeltaub, R., … Stamp, L. K., … Chapman, P., … Grainger, R., … Taylor, W. J. (2013). A Delphi exercise to identify characteristic features of gout: Opinions from patients and physicians, the first stage in developing new classification criteria. Journal of Rheumatology, 40(4), 498-505. doi: 10.3899/jrheum.121037

Stamp, L. K., & Chapman, P. T. (2012). Gout and organ transplantation. Current Rheumatology Reports, 14(2), 165-172. doi: 10.1007/s11926-012-0235-9

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2012). Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: Implications for clinical practice. Rheumatology, 51(9), 1670-1676. doi: 10.1093/rheumatology/kes091

Raja, R., Chapman, P. T., O'Donnell, J. L., Ipenburg, J., Frampton, C., Hurst, M., & Stamp, L. K. (2012). Comparison of the 2010 American College of Rheumatology/European League Against Rheumatism and the 1987 American Rheumatism Association classification criteria for rheumatoid arthritis in an early arthritis cohort in New Zealand. Journal of Rheumatology, 39(11). doi: 10.3899/jrheum.120226

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Relationship between serum urate and plasma oxypurinol in the management of gout: Determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics, 90(3), 392-398. doi: 10.1038/clpt.2011.113

Stamp, L. K., & Chapman, P. (2011). Existing and emerging therapies for acute gout and long-term urate lowering. Current Rheumatology Reviews, 7(2), 141-151. doi: 10.2174/157339711795305031

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011). Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including in those with renal impairment. Arthritis & Rheumatism, 63(2), 412-421. doi: 10.1002/art.30119

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Journal of Rheumatology, 38(12), 2540-2547. doi: 10.3899/jrheum.110481

White, D. H. N., Chapman, P. T., O'Donnell, J. L., James, J., Frampton, C., & Stamp, L. K. (2010). Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Internal Medicine Journal, 40(8), 561-565. doi: 10.1111/j.1445-5994.2009.02059.x

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., & Roberts, R. L. (2010). Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics & Genomics, 20(6), 367-376. doi: 10.1097/FPC.0b013e3283398a71

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., & Barclay, M. L. (2010). Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis & Rheumatism, 62(2), 359-368. doi: 10.1002/art.27201

Hollis-Moffatt, J. E., Merriman, M. E., Green, R. A., Rowley, K. A., Chapman, P. T., Dalbeth, N., … Harrison, A. A., Highton, J., … O'Donnell, J. L., Stamp, L. K., & Merriman, T. R. (2009). Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Annals of the Rheumatic Diseases, 68(8), 1340-1344. doi: 10.1136/ard.2008.090142

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis & Rheumatism, 60(8), 2248-2256. doi: 10.1002/art.24653

Taylor, W. J., Harrison, A. A., Highton, J., Chapman, P., Stamp, L., Dockerty, J., … Sew Hoy, M. (2008). Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology, 47, 514-518. doi: 10.1093/rheumatology/ken004

Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism, 58(11), 3299-3308.

Taylor, W. J., Schumacher, Jr, H. R., Baraf, H. S. B., Chapman, P., Stamp, L., Doherty, M., … Grainger, R., … Barskova, V. G. (2008). A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Annals of the Rheumatic Diseases, 67(6), 888-891. doi: 10.1136/ard.2007.079970

McKinney, C., Merriman, M. E., Chapman, P. T., Gow, P. J., Harrison, A. A., Highton, J., … O'Donnell, J. L., … Stamp, L. K., Willis, J., … Merriman, T. R. (2008). Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Annals of the Rheumatic Diseases, 67, 409-413. doi: 10.1136/ard.2007.075028

O'Donnell, J. L., Stevanovic, V. R., Frampton, C., Stamp, L. K., & Chapman, P. T. (2007). Wegener's granulomatosis in New Zealand: Evidence for a latitude-dependent incidence gradient. Internal Medicine Journal, 37, 242-246.

Steer, S., Abkevich, V., Gutin, A., Cordell, H. J., Gendall, K. L., Merriman, M. E., Green, R. A., Rowley, K. A., Chapman, P., … Harrison, A. A., Highton, J., … O'Donnell, J., Stamp, L., … Merriman, T. R. (2007). Genomic DNA pooling for whole-genome association scans in complex disease: Empirical demonstration of efficacy in rheumatoid arthritis. Genes & Immunity, 8, 57-68. doi: 10.1038/sj.gene.6364359

Jenks, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in rheumatoid arthritis. Journal of Rheumatology, 34, 2201-2203.

O'Donnell, J. L., Hayman, M. W., Spellerberg, M. B., McLellan, A. D., Brooksbank, K., Chapman, P. T., & Stamp, L. K. (2007). Antineutrophil cytoplasmic antibody measurement: Advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA. Pathology, 39(2), 258-263.

Stamp, L. K., O'Donnell, J. L., & Chapman, P. T. (2007). Emerging therapies in the long-term management of hyperuricaemia and gout. Internal Medicine Journal, 37, 258-266.

Meuli, K., Chapman, P., O'Donnell, J., Frampton, C., & Stamp, L. (2007). Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Internal Medicine Journal, 37, 687-692.

Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. (2006). Pneumonitis associated with leflunomide: A profile of New Zealand and Australian reports. Internal Medicine Journal, 36, 162-169.

Stamp, L., Ha, L., Searle, M., O'Donnell, J., Frampton, C., & Chapman, P. (2006). Gout in renal transplant recipients. Nephrology, 11(4), 367-371. doi: 10.1111/j.1440-1797.2006.00577.x

Gibson, A., Stamp, L. K., Chapman, P. T., & O'Donnell, J. L. (2006). The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology, 45, 624-628. doi: 10.1093/rheumatology/kei259

More publications...